Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0L7LC
|
||||
| Former ID |
DCL000317
|
||||
| Drug Name |
Romidepsin
|
||||
| Synonyms |
Chromadax; Istodax; Antibiotic FR 901228; FK 228; FK228; FR 901228; FR901228; HDInhib_000006; Chromadax (TN); FK-228; FK-901228; FR-901228; Istodax (TN); Romidepsin (USAN); Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (35)-disulfide; L-Valine, N-((3S,4E)-3-hydroxy-7-mercapto-1-oxo-4-heptenyl)-D-valyl-D-cysteinyl-(2Z)-2-amino-2-butenoxyl-, (4-1)-lactone, cyclic (1-2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo(8.7.6)tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Cutaneous T-cell lymphoma [ICD9: 202.1, 202.2; ICD10:C84.0, C84.1] | Approved | [530677], [542036] | ||
| Renal cell carcinoma; Hormone refractory prostate cancer [ICD9: 140-229, 185, 189, 203.0, 205.0; ICD10:C61, C64, C90.0, C92.0] | Phase 3 | [530677], [542036] | |||
| Peripheral T-cell lymphoma [ICD9: 202.7; ICD10:C84.4] | Phase 2 | [530677], [542036] | |||
| Company |
Gloucester Pharmaceuticals; Fujisawa Pharmaceutical Ltd.
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C24H36N4O6S2
|
||||
| InChI |
InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1
|
||||
| InChIKey |
OHRURASPPZQGQM-GCCNXGTGSA-N
|
||||
| CAS Number |
CAS 128517-07-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
494874, 8139716, 11650994, 12014448, 14763476, 14763478, 35018633, 46519185, 47208288, 47721651, 47944836, 48394948, 50062237, 50260193, 53788098, 57361456, 87226502, 103393180, 104222481, 113905898, 127325932, 127325933, 131408687, 134338801, 134338973, 134340279, 137156420, 139110210, 152159610, 163620827, 163686155, 164233439, 175266198, 176484649, 178103585, 184816960, 198992824, 224274473, 226087966, 226972555, 251894761, 252430794, 252450287, 252473284
|
||||
| SuperDrug ATC ID |
L01XX39
|
||||
| Target and Pathway | |||||
| Target(s) | Histone deacetylase 1 | Target Info | Inhibitor | [530677] | |
| NetPath Pathway | TCR Signaling Pathway | ||||
| PANTHER Pathway | Wnt signaling pathway | ||||
| p53 pathway | |||||
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
| Notch signaling pathway | |||||
| E2F transcription factor network | |||||
| Presenilin action in Notch and Wnt signaling | |||||
| Signaling events mediated by HDAC Class I | |||||
| Regulation of Telomerase | |||||
| Glucocorticoid receptor regulatory network | |||||
| Sumoylation by RanBP2 regulates transcriptional repression | |||||
| Regulation of Androgen receptor activity | |||||
| IL3-mediated signaling events | |||||
| Validated nuclear estrogen receptor alpha network | |||||
| Retinoic acid receptors-mediated signaling | |||||
| Hedgehog signaling events mediated by Gli proteins | |||||
| Regulation of nuclear beta catenin signaling and target gene transcription | |||||
| Validated targets of C-MYC transcriptional repression | |||||
| Regulation of retinoblastoma protein | |||||
| Notch-mediated HES/HEY network | |||||
| Reactome | G0 and Early G1 | ||||
| p75NTR negatively regulates cell cycle via SC1 | |||||
| Formation of the beta-catenin:TCF transactivating complex | |||||
| NOTCH1 Intracellular Domain Regulates Transcription | |||||
| SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription | |||||
| Constitutive Signaling by NOTCH1 PEST Domain Mutants | |||||
| Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants | |||||
| HDACs deacetylate histones | |||||
| Deactivation of the beta-catenin transactivating complex | |||||
| NoRC negatively regulates rRNA expression | |||||
| RNA Polymerase I Transcription Initiation | |||||
| Factors involved in megakaryocyte development and platelet production | |||||
| WikiPathways | SIDS Susceptibility Pathways | ||||
| Notch Signaling Pathway | |||||
| TGF beta Signaling Pathway | |||||
| IL-6 signaling pathway | |||||
| Apoptosis-related network due to altered Notch3 in ovarian cancer | |||||
| Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer | |||||
| Notch Signaling Pathway | |||||
| Retinoblastoma (RB) in Cancer | |||||
| Neural Crest Differentiation | |||||
| TWEAK Signaling Pathway | |||||
| Integrated Breast Cancer Pathway | |||||
| Signalling by NGF | |||||
| RNA Polymerase I, RNA Polymerase III, and Mitochondrial Transcription | |||||
| Mitotic G1-G1/S phases | |||||
| Factors involved in megakaryocyte development and platelet production | |||||
| Cell Cycle | |||||
| Androgen receptor signaling pathway | |||||
| References | |||||
| Ref 530677 | Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92. | ||||
| Ref 542036 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7006). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.